Skip to main content

Cepheid Names Vysis Chief to Be CEO

NEW YORK, April 15 - Cepheid said today it has hired John L. Bishop to be CEO.

Bishop, who will also become a member of Cepheid's board, succeeds co-founder Thomas L. Gutshall, who will continue as chairman.


"Clinical diagnostics represents a major untapped opportunity for Cepheid's DNA testing products, and John's outstanding record of success in creating and expanding new markets will be a tremendous asset," Gutshall said in a statement.

Before joining Cepheid, Bishop was president and CEO of Vysis, which he helped create. Bishop took the company public in 1998, and oversaw its sale to Abbott Laboratories in December 2001 for roughly $355 million.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.